USPTO serial 97887000
SIGRID
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PATEL, SAMIR RAMESH
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with SIGRID?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley L. Cohn
Bradley L. Cohn PATTISHALL, MCAULIFFE, NEWBURY, HILLIARD & GERALDS125 SOUTH WACKER DRIVE, SUITE 2050CHICAGO, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; pharmaceutical preparations and natural remedy preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemical pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure; dietary supplements for humans; dietary supplements for the support of healthy blood sugar levels, weight levels, cholesterol levels, blood pressure levels, and energy levels; vitamin supplements; mineral supplements; food supplements; nutritional supplements | ACTIVE | — |
| 010 | Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated medical devices, and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, and post bariatric surgery patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 1, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 30, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 30, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 30, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 9, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 9, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 9, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 2, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 1, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 1, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 1, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 30, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 30, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 30, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 30, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 2, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 26, 2024 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 25, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| May 17, 2024 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| May 7, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 7, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 1, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 7, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 7, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 8, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 17, 2023 | NWAP | NEW APPLICATION ENTERED | — |